SETD2 loss-of-function mutations were observed in 10% of primary and 30% of metastatic ccRCC tumors, whereas H3K36 methylation is significantly reduced in ccRCC cell lines and patient samples [56]. The gene discussed is SETD2; the disease is nonpapillary renal cell carcinoma.